Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alteon, Inc.
Alagebrium demonstrates benefits on heart, kidney in preclinical studies
June 26th, 2004
Alteon, Inc., (ALT) announced that an abstract detailing the effects of Alteon's A.G.E. Crosslink Breaker alagebrium (formerly ALT-711) in the treatment of aged spontaneously hypertensive rats was presented at the American Society of Hypertension Nineteenth Annual Scientific Meeting and Exposition in New York City. In addition, the abstract and a separate paper were recently published in the American Journal of Hypertension. Study results showed that alagebrium therapy demonstrated beneficial cardiovascular and renal effects by reducing systolic blood pressure, left ventricular mass and urinary protein excretion, as well as improving left ventricular (LV)...
Source: Law & Health Weekly (2004-06-26)
|
